Ibuprofen Suppresses Interleukin-1β Induction of Pro-Amyloidogenic α1-Antichymotrypsin to Ameliorate β-Amyloid (Aβ) Pathology in Alzheimer's Models

[1]  S. Kannan,et al.  Dynamics of cellular entry and drug delivery by dendritic polymers into human lung epithelial carcinoma cells , 2004, Journal of biomaterials science. Polymer edition.

[2]  J. Shioi,et al.  Cyclooxygenase (COX)-2 and COX-1 Potentiate β-Amyloid Peptide Generation through Mechanisms That Involve γ-Secretase Activity* , 2003, Journal of Biological Chemistry.

[3]  Valentina Gelfanova,et al.  Nonsteroidal Anti-Inflammatory Drugs Can Lower Amyloidogenic Aß42 by Inhibiting Rho , 2003, Science.

[4]  Thomas Klockgether,et al.  Nonsteroidal Anti-Inflammatory Drugs and Peroxisome Proliferator-Activated Receptor-γ Agonists Modulate Immunostimulated Processing of Amyloid Precursor Protein through Regulation of β-Secretase , 2003, The Journal of Neuroscience.

[5]  S. Weggen,et al.  The Non-cyclooxygenase Targets of Non-steroidal Anti-inflammatory Drugs, Lipoxygenases, Peroxisome Proliferator-activated Receptor, Inhibitor of κB Kinase, and NFκB, Do Not Reduce Amyloid β42 Production* , 2003, Journal of Biological Chemistry.

[6]  S. Weggen,et al.  Evidence That Nonsteroidal Anti-inflammatory Drugs Decrease Amyloid β42 Production by Direct Modulation of γ-Secretase Activity* , 2003, Journal of Biological Chemistry.

[7]  M. Citron,et al.  Anti-Inflammatory Drug Therapy Alters β-Amyloid Processing and Deposition in an Animal Model of Alzheimer's Disease , 2003, The Journal of Neuroscience.

[8]  S. Weggen,et al.  Aβ42-lowering Nonsteroidal Anti-inflammatory Drugs Preserve Intramembrane Cleavage of the Amyloid Precursor Protein (APP) and ErbB-4 Receptor and Signaling through the APP Intracellular Domain* , 2003, Journal of Biological Chemistry.

[9]  Patrick L. McGeer,et al.  Inflammatory processes in Alzheimer's disease , 2003, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[10]  Pritam Das,et al.  NSAIDs and enantiomers of flurbiprofen target γ-secretase and lower Aβ42 in vivo , 2003 .

[11]  T. Iwatsubo,et al.  Sulindac Sulfide Is a Noncompetitive γ-Secretase Inhibitor That Preferentially Reduces Aβ42 Generation* , 2003, The Journal of Biological Chemistry.

[12]  T. Montine,et al.  Inflammation and cerebral amyloidosis are disconnected in an animal model of Alzheimer's disease , 2003, Journal of Neuroimmunology.

[13]  Takashi Morihara,et al.  Selective inhibition of Aβ42 production by NSAID R‐enantiomers , 2002 .

[14]  P. Zandi,et al.  Reduced incidence of AD with NSAID but not H2 receptor antagonists: The Cache County Study , 2002, Neurology.

[15]  S. DeKosky,et al.  Distribution of plasma α1-antichymotrypsin levels in Alzheimer disease patients and controls and their genetic controls , 2002, Neurobiology of Aging.

[16]  D. Borchelt,et al.  Cyclooxygenase (COX)-2 and cell cycle activity in a transgenic mouse model of Alzheimer’s Disease neuropathology , 2002, Neurobiology of Aging.

[17]  A. Fagan,et al.  Human and Murine ApoE Markedly Alters Aβ Metabolism before and after Plaque Formation in a Mouse Model of Alzheimer's Disease , 2002, Neurobiology of Disease.

[18]  S. DeKosky,et al.  Genetic variation in α1-antichymotrypsin and its association with Alzheimer’s disease , 2002, Human Genetics.

[19]  D. Coppola,et al.  Microglial Activation and β-Amyloid Deposit Reduction Caused by a Nitric Oxide-Releasing Nonsteroidal Anti-Inflammatory Drug in Amyloid Precursor Protein Plus Presenilin-1 Transgenic Mice , 2002, The Journal of Neuroscience.

[20]  C. Meinert,et al.  Double placebo design in a prevention trial for Alzheimer's disease. , 2002, Controlled clinical trials.

[21]  Rong Wang,et al.  A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity , 2001, Nature.

[22]  G. M. Cole,et al.  Phenolic anti-inflammatory antioxidant reversal of Aβ-induced cognitive deficits and neuropathology , 2001, Neurobiology of Aging.

[23]  R. Mrak,et al.  Interleukin-1, neuroinflammation, and Alzheimer’s disease , 2001, Neurobiology of Aging.

[24]  J. Overmier,et al.  Ibuprofen effects on Alzheimer pathology and open field activity in APPsw transgenic mice , 2001, Neurobiology of Aging.

[25]  Gerd Geisslinger,et al.  Cyclooxygenase‐independent actions of cyclooxygenase inhibitors , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[26]  S. Paul,et al.  Neuroinflammation‐induced acceleration of amyloid deposition in the APPV717F transgenic mouse , 2001, The European journal of neuroscience.

[27]  I. Kola,et al.  BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics. , 2001, Human molecular genetics.

[28]  S. Paul,et al.  Neuronal injury-induced expression and release of apolipoprotein E in mixed neuron/glia co-cultures: nuclear factor κB inhibitors reduce basal and lesion-induced secretion of apolipoprotein E , 2001, Neuroscience.

[29]  S. Paul,et al.  α-1-Antichymotrypsin Promotes β-Sheet Amyloid Plaque Deposition in a Transgenic Mouse Model of Alzheimer's Disease , 2001, The Journal of Neuroscience.

[30]  Mikio Shoji,et al.  Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease , 2001, The Journal of Neuroscience.

[31]  L. Mucke,et al.  Astroglial expression of human alpha(1)-antichymotrypsin enhances alzheimer-like pathology in amyloid protein precursor transgenic mice. , 2000, The American journal of pathology.

[32]  R. Rydel,et al.  Mechanism of Interleukin-1- and Tumor Necrosis Factor α-Dependent Regulation of the α1-Antichymotrypsin Gene in Human Astrocytes , 2000, The Journal of Neuroscience.

[33]  G. Annoni,et al.  Gene polymorphism affecting α1‐antichymotrypsin and interleukin‐1 plasma levels increases Alzheimer's disease risk , 2000, Annals of neurology.

[34]  K. Ashe,et al.  Ibuprofen Suppresses Plaque Pathology and Inflammation in a Mouse Model for Alzheimer's Disease , 2000, The Journal of Neuroscience.

[35]  W. Griffin,et al.  Interleukin‐1 and the Immunogenetics of Alzheimer Disease , 2000, Journal of neuropathology and experimental neurology.

[36]  C. Plata-salamán,et al.  Inflammation and Alzheimer’s disease , 2000, Neurobiology of Aging.

[37]  L. Murray,et al.  Association of interleukin‐1 gene polymorphisms with Alzheimer's disease , 2000, Annals of neurology.

[38]  P. May,et al.  Regulation of Cytokine Secretion and Amyloid Precursor Protein Processing by Proinflammatory Amyloid Beta (Aβ) , 2000 .

[39]  A. Delacourte,et al.  Synthesis of apolipoprotein E (ApoE) mRNA by human neuronal-type SK N SH-SY 5Y cells and its regulation by nerve growth factor and ApoE , 1999, Neuroscience Letters.

[40]  R. Martins,et al.  The -491AA polymorphism in the APOE gene is associated with increased plasma apoE levels in Alzheimer's disease. , 1999, Neuroreport.

[41]  P. Mcgeer,et al.  Up-regulated production and activation of the complement system in Alzheimer's disease brain. , 1999, The American journal of pathology.

[42]  A. Hofman,et al.  The −491 A/T polymorphism in the regulatory region of the Apolipoprotein E gene and early-onset Alzheimer's disease , 1998, Neuroscience Letters.

[43]  E. Masliah,et al.  Increased levels of α-1-antichymotrypsin in brains of patients with Alzheimer's disease correlate with activated astrocytes and are affected by APOE 4 genotype , 1998, Journal of Neuroimmunology.

[44]  M. Freedman,et al.  Absence of association between Alzheimer disease and the −491 regulatory region polymorphism of APOE , 1998, Neuroscience Letters.

[45]  F. Pasquier,et al.  A new polymorphism in the APOE promoter associated with risk of developing Alzheimer's disease. , 1998, Human molecular genetics.

[46]  N. Davies,et al.  Clinical Pharmacokinetics of Ibuprofen , 1998, Clinical pharmacokinetics.

[47]  J. Victoroff,et al.  Increased Apolipoprotein E mRNA in the Hippocampus in Alzheimer Disease and in Rats after Entorhinal Cortex Lesioning , 1998, Experimental Neurology.

[48]  T. McNeill,et al.  Differential Regulation of Astrocytic mRNAs in the Rat Striatum after Lesions of the Cortex or Substantia Nigra , 1998, Experimental Neurology.

[49]  J. Hardy,et al.  Distortion of allelic expression of apolipoprotein E in Alzheimer's disease. , 1997, Human molecular genetics.

[50]  M. Gearing,et al.  Astrocyte‐Apolipoprotein E Associations in Senile Plaques in Alzheimer Disease and Vascular Lesions: A Regional Immunohistochemical Study , 1997, Journal of neuropathology and experimental neurology.

[51]  W F Stewart,et al.  Risk of Alzheimer's disease and duration of NSAID use , 1997, Neurology.

[52]  Patrick L. McGeer,et al.  Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease , 1996, Neurology.

[53]  A. Kling,et al.  Serum α1-antichymotrypsin level as a marker for Alzheimer-type dementia , 1995, Neurobiology of Aging.

[54]  S. Hirai,et al.  Alpha1-Antichymotrypsin Level in Cerebrospinal Fluid Is Closely Associated with Late Onset Alzheimer's Disease , 1995 .

[55]  J. Tateishi,et al.  Apolipoprotein E mRNA in the brains of patients with Alzheimer's disease , 1995, Journal of the Neurological Sciences.

[56]  Saumya Das,et al.  Expression of the Alzheimer amyloid-promoting factor antichymotrypsin is induced in human astrocytes by IL-1 , 1995, Neuron.

[57]  H. Brewer,et al.  Amyloid-associated proteins α1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer β-protein into filaments , 1994, Nature.

[58]  C. Finch,et al.  Glial Fibrillary Acidic Protein: Regulation by Hormones, Cytokines, and Growth Factors , 1994, Brain pathology.

[59]  W. McDonald,et al.  Inverse association of anti‐inflammatory treatments and Alzheimer's disease , 1994, Neurology.

[60]  T. Morgan,et al.  Transforming growth factor-β1 induces neuronal and astrocyte genes: Tubulin α1, glial fibrillary acidic protein and clusterin , 1994, Neuroscience.

[61]  C. Finch,et al.  Astrocytic apolipoprotein E mRNA and GFAP mRNA in hippocampus after entorhinal cortex lesioning. , 1991, Brain research. Molecular brain research.

[62]  D. Price,et al.  Developmental expression of α1-antichymotrypsin in brain may be related to astrogliosis , 1991, Neurobiology of Aging.

[63]  A. Haase,et al.  Neuropathological changes in scrapie and Alzheimer's disease are associated with increased expression of apolipoprotein E and cathepsin D in astrocytes , 1991, Journal of virology.

[64]  S. Hirai,et al.  α1‐Antichymotrypsin as a possible biochemical marker for Alzheimer‐type dementia , 1990 .

[65]  M. Connell,et al.  Estimation of the in vivo effect of cyclooxygenase inhibitors on prostaglandin E2 levels in mouse brain. , 1990, European journal of pharmacology.

[66]  D. Selkoe,et al.  Immunochemical identification of the serine protease inhibitor α 1-antichymotrypsin in the brain amyloid deposits of Alzheimer's disease , 1988, Cell.

[67]  K. McCarthy,et al.  Preparation of separate astroglial and oligodendroglial cell cultures from rat cerebral tissue , 1980, The Journal of cell biology.

[68]  Michael T Heneka,et al.  Nonsteroidal anti-inflammatory drugs and peroxisome proliferator-activated receptor-gamma agonists modulate immunostimulated processing of amyloid precursor protein through regulation of beta-secretase. , 2003, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[69]  T. Iwatsubo,et al.  Sulindac sulfide is a noncompetitive gamma-secretase inhibitor that preferentially reduces Abeta 42 generation. , 2003, The Journal of biological chemistry.

[70]  J. Shioi,et al.  Cyclooxygenase (COX)-2 and COX-1 potentiate beta-amyloid peptide generation through mechanisms that involve gamma-secretase activity. , 2003, The Journal of biological chemistry.

[71]  Pritam Das,et al.  NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. , 2003, The Journal of clinical investigation.

[72]  F. Liu,et al.  Nonsteroidal anti-inflammatory drugs can lower amyloidogenic Abeta42 by inhibiting Rho. , 2003, Science.

[73]  K. Matsuda,et al.  Internalization of beta-amyloid causes downregulation of apolipoprotein E mRNA expression in neuroblastoma cells. , 2003, Annals of clinical and laboratory science.

[74]  S. Weggen,et al.  The non-cyclooxygenase targets of non-steroidal anti-inflammatory drugs, lipoxygenases, peroxisome proliferator-activated receptor, inhibitor of kappa B kinase, and NF kappa B, do not reduce amyloid beta 42 production. , 2003, The Journal of biological chemistry.

[75]  S. Weggen,et al.  Evidence that nonsteroidal anti-inflammatory drugs decrease amyloid beta 42 production by direct modulation of gamma-secretase activity. , 2003, The Journal of biological chemistry.

[76]  L. Walker,et al.  Cerebral beta-amyloid deposition is augmented by the -491AA promoter polymorphism in non-demented elderly individuals bearing the apolipoprotein E epsilon4 allele. , 2003, Acta neuropathologica.

[77]  S. DeKosky,et al.  Genetic variation in alpha(1)-antichymotrypsin and its association with Alzheimer's disease. , 2002, Human genetics.

[78]  G. Cole,et al.  Selective inhibition of Abeta42 production by NSAID R-enantiomers. , 2002, Journal of neurochemistry.

[79]  L. Walker,et al.  Cerebral β-amyloid deposition is augmented by the –491AA promoter polymorphism in non-demented elderly individuals bearing the apolipoprotein E ε4 allele , 2002, Acta Neuropathologica.

[80]  S. Younkin,et al.  Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. , 2001, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[81]  S. Paul,et al.  Alpha-1-antichymotrypsin promotes beta-sheet amyloid plaque deposition in a transgenic mouse model of Alzheimer's disease. , 2001, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[82]  W. Richards,et al.  Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation. , 2001, Nature neuroscience.

[83]  H. Cai,et al.  BACE1 is the major beta-secretase for generation of Abeta peptides by neurons. , 2001, Nature neuroscience.

[84]  R. Rydel,et al.  Mechanism of interleukin-1- and tumor necrosis factor alpha-dependent regulation of the alpha 1-antichymotrypsin gene in human astrocytes. , 2000, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[85]  G. Cole,et al.  Methods for Evaluating in Vivo Rodent Models for Alzheimer’s Disease , 1999 .

[86]  J. Morris,et al.  A polymorphism in the regulatory region of APOE associated with risk for Alzheimer's dementia , 1998, Nature Genetics.

[87]  G. Cryer,et al.  Regulation of macrophage eicosanoid generation is dependent on nuclear factor kappaB. , 1998, The Journal of trauma.

[88]  S. Paul,et al.  Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. , 1997, Nature genetics.

[89]  J. Bauer,et al.  Interleukin-1 beta and tumor necrosis factor-alpha induce expression of alpha 1-antichymotrypsin in human astrocytoma cells by activation of nuclear factor-kappa B. , 1996, Journal of neurochemistry.

[90]  S. Hirai,et al.  Alpha 1-antichymotrypsin level in cerebrospinal fluid is closely associated with late onset Alzheimer's disease. , 1995, Internal medicine.

[91]  A. Kling,et al.  Serum alpha 1-antichymotrypsin level as a marker for Alzheimer-type dementia. , 1995, Neurobiology of aging.

[92]  D. Cucinotta,et al.  Acute Phase Reactant α1Antichymotrypsin Is Increased in Cerebrospinal Fluid and Serum of Patients with Probable Alzheimer Disease , 1995, Alzheimer disease and associated disorders.

[93]  J. Ma,et al.  Amyloid-associated proteins alpha 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer beta-protein into filaments. , 1994, Nature.

[94]  T. Morgan,et al.  Transforming growth factor-beta 1 induces neuronal and astrocyte genes: tubulin alpha 1, glial fibrillary acidic protein and clusterin. , 1994, Neuroscience.

[95]  D. Price,et al.  Developmental expression of alpha 1-antichymotrypsin in brain may be related to astrogliosis. , 1991, Neurobiology of aging.

[96]  S. Hirai,et al.  Alpha 1-antichymotrypsin is present in diffuse senile plaques. A comparative study of beta-protein and alpha 1-antichymotrypsin immunostaining in the Alzheimer brain. , 1991, The American journal of pathology.

[97]  S. Hirai,et al.  Alpha 1-antichymotrypsin as a possible biochemical marker for Alzheimer-type dementia. , 1990, Annals of neurology.

[98]  S. Younkin,et al.  Astrocytes in Alzheimer's disease gray matter express alpha 1-antichymotrypsin mRNA. , 1989, The American journal of pathology.

[99]  A. Lbert,et al.  Nonsteroidal Antiinflammatory Drugs and the Risk of Alzheimer's Disease , 2022 .